Skip to main content

Two medicines, side by side

Captopril vs carvedilol

Captopril and carvedilol are both labeled for high blood pressure and heart failure. Drugs@FDA records approvals of captopril since 1981 and of carvedilol since 1995. Pharmacies paid $0.228 per captopril 12.5 mg tablet and $0.0179 per carvedilol 6.25 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, captopril is an angiotensin converting enzyme inhibitor and carvedilol an alpha-adrenergic blocker.

Check it at the source: the captopril FDA label on DailyMed (effective February 6, 2026); the carvedilol FDA label on DailyMed (effective July 31, 2026).

Highlights of the captopril record

Captopril (Capoten) · label of February 6, 2026

Boxed warning

FETAL TOXICITY When pregnancy is detected, discontinue captopril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity

Used for

From the label: indications

Hypertension Captopril tablets are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. […]

On the market

Earliest approval on file
April 6, 1981
Generic labelers
13 labelers
Pharmacy cost
$0.228 per tablet

Supply and safety

Shortage
No current entry
Recalls
5

Highlights of the carvedilol record

Carvedilol (Coreg) · label of July 31, 2026

Used for

From the label: indications

INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in […]

On the market

Earliest approval on file
September 14, 1995
Generic labelers
41 labelers
Pharmacy cost
$0.0179 per tablet

Supply and safety

Shortage
No current entry
Recalls
22

Source: FDA drug labels via openFDA (Captopril label of February 6, 2026, Carvedilol label of July 31, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)

How do captopril and carvedilol differ on the record?

In FDA's classes, captopril is an angiotensin converting enzyme inhibitor and carvedilol an alpha-adrenergic blocker.

Half-life, in each label's words: Captopril, “The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.”; Carvedilol, “Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 …”

Only the captopril label carries a boxed warning.

Generics: captopril since 1995; carvedilol since 2007 (Drugs@FDA).

CaptoprilCarvedilol
Labeled forHigh blood pressure, Heart failure, Chronic kidney diseaseHeart failure, High blood pressure
Pharmacologic classAngiotensin Converting Enzyme Inhibitoralpha-Adrenergic Blocker, beta-Adrenergic Blocker
How it works (label)n/aCOREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency.
Half-life (label)The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours.Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
Earliest approval on file (Drugs@FDA)April 6, 1981September 14, 1995
First generic approvedMarch 31, 1995September 5, 2007
Generic labelers (NDC)13 labelers41 labelers
Pharmacy cost (NADAC, each one's most listed form; strengths differ)$0.228 per tablet (Captopril 12.5 mg tablet)$0.0179 per tablet (Carvedilol 6.25 mg tablet)
12-month price change-28%-4%
Boxed warningYesNo
Shortage nowNo current entryNo current entry
Recalls recorded522
FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used)9,557137,029
DEA schedulenonenone

Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)

What next?

Alternatives to captopril
every medicine labeled for the same conditions